Reviva: Providing a Major Breakthrough for Mental Health and Schizophrenia

Reviva (Nasdaq: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for Q3 2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries. Learn more at RVPHinfo.com.